Humana Inc. (NYSE:HUM)’s share price shot up 7.6% during trading on Thursday . The company traded as high as $170.97 and last traded at $170.47, with a volume of 5,809,687 shares. The stock had previously closed at $158.41.

A number of research firms have commented on HUM. JPMorgan Chase & Co. lowered Humana from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $196.00 to $150.00 in a research note on Friday, July 8th. Zacks Investment Research downgraded Humana from a “hold” rating to a “sell” rating in a report on Tuesday, April 26th. Jefferies Group raised Humana from a “hold” rating to a “buy” rating and raised their target price for the company from $158.89 to $210.00 in a report on Monday. Wolfe Research initiated coverage on Humana in a report on Tuesday, June 28th. They issued a “market perform” rating and a $244.00 target price on the stock. Finally, Stifel Nicolaus raised their target price on Humana from $209.00 to $220.00 and gave the company a “buy” rating in a report on Thursday, May 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $206.36.

The firm has a 50-day moving average of $177.05 and a 200-day moving average of $174.38. The firm has a market capitalization of $25.56 billion and a PE ratio of 23.91.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, May 4th. The insurance provider reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.81 by $0.05. The firm earned $13.80 billion during the quarter, compared to the consensus estimate of $13.80 billion. During the same period in the previous year, the company posted $2.58 EPS. The company’s revenue for the quarter was down .2% compared to the same quarter last year. On average, equities research analysts predict that Humana Inc. will post $8.87 earnings per share for the current year.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley boosted its position in Humana by 68.6% in the fourth quarter. Morgan Stanley now owns 1,347,032 shares of the insurance provider’s stock valued at $240,459,000 after buying an additional 547,940 shares during the last quarter. Whitebox Advisors LLC boosted its position in Humana by 282.1% in the fourth quarter. Whitebox Advisors LLC now owns 250,507 shares of the insurance provider’s stock valued at $44,718,000 after buying an additional 184,940 shares during the last quarter. Vanguard Group Inc. boosted its position in Humana by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 8,460,931 shares of the insurance provider’s stock valued at $1,510,361,000 after buying an additional 181,672 shares during the last quarter. Marshall Wace LLP boosted its position in Humana by 450.5% in the fourth quarter. Marshall Wace LLP now owns 171,008 shares of the insurance provider’s stock valued at $30,527,000 after buying an additional 139,942 shares during the last quarter. Finally, BBR Partners LLC purchased a new position in Humana during the fourth quarter valued at $23,699,000.

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.